Max Senna Mano

19PUBLICATIONS
110CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Oct 01, 2026
Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2-Negative Breast Cancer: A Real-World Study.

|Mar 11, 2026
Financial Toxicity in Patients With Breast Cancer Treated at Private Medicine Institutions in Brazil.

Aline Cristini Vieira, Matheus Costa E Silva, Cristiano De Padua Souza

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Jan 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Ivan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira

|Oct 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Carlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira

|Jul 14, 2025
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives.

Jessé Lopes da Silva, Leandro Jonata de Carvalho Oliveira, Cristiano Augusto Andrade de Resende

Pageof 4

Frequent Collaborators

8 joint publications

Leandro Jonata de Carvalho Oliveira

5 joint publications

Tomas Reinert

4 joint publications

Andrea Kazumi Shimada

3 joint publications

Carlos Henrique Dos Anjos